 |
59 Diseases |  |
24 Trials |
|
24 Trials |  |
1996 News |  |
| «12...7891011121314151617...2526» |
- Xcopri (cenobamate) / SK Bio, Angelini Group
Meta-Analysis/Indirect Treatment Comparison of Cenobamate to Other ASMs for the Treatment of Uncontrolled Focal Seizures () - Dec 12, 2021 - Abstract #AES2021AES_1355;
Cenobamate was compared to a group of 7 other ASMs, and to subgroups of branded (brivaracetam, eslicarbazepine acetate, lacosamide, perampanel) and older ASMs (lamotrigine, levetiracetam, topiramate) at FDA-recommended daily maintenance doses (FDA-RDMD) and all doses. Statistical significance was set at P < 0.05.
- Xcopri (cenobamate) / SK Bio, Angelini Group
Effectiveness and Safety of Adjunctive Cenobamate for Uncontrolled Focal Seizures in Routine Clinical Practice with Patients Living in a Group Home or with a Developmental Disability () - Dec 12, 2021 - Abstract #AES2021AES_1314;
During routine clinical practice for the treatment of uncontrolled focal seizures in patients living in a group home or living with developmental disability, substantial reduction in seizure frequency and high responder rates, including seizure freedom, occurred with adjunctive cenobamate. Treatment was well tolerated and SE were often mitigated or resolved following reduction of concomitant ASMs.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
On the Digital Psychopharmacology of Antiseizure Medications () - Dec 12, 2021 - Abstract #AES2021AES_1285;
Our data demonstrate that experimenter-free instrumented home cage chambers can reveal unique psychopharmacological profiles for ASMs with distinct mechanisms of action, providing protocols for the screening of pipeline ASM candidates and models that may predict ASM side effects. In ongoing experiments, we extend this analysis to a third water soluble ASM (lacosamide), and explore the effects of ASM polytherapy and dose dependence.
- Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Time to reach Maintenance dose in Patients with Focal Seizures initiating Eslicarbazepine acetate in a real-world setting () - Dec 12, 2021 - Abstract #AES2021AES_1271;
Most used ASDs in the baseline were: levetiracetam (32.3%), lamotrigine (19.3%), oxcarbazepine (16.5%) and lacosamide (14.1%). This real-world study suggests patients with FS initiating ESL, took 15 days to reach maintenance dose, with >50% of the patients initiating at their maintenance dose.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo, lamotrigine liquid oral suspension / OWP Pharma, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Transient Atrial Fibrillation Following Generalized Tonic-Clonic Seizure in Epileptic Patients with HIV () - Dec 12, 2021 - Abstract #AES2021AES_1253;
Appropriate management for AF should be considered after weighing the risk and benefits. Further studies with larger sample size are needed to assess any possible association between the increased risk for postictal AF after GTCS in epileptic patients with HIV.
- ketamine / Generic mfg., lorazepam / Generic mfg.
Responsive NeuroStimulation Treatment in a Patient with Super Refractory Status Epilepticus Arising from Eloquent Cortex () - Dec 12, 2021 - Abstract #AES2021AES_1233;
Usual treatment options include ASMs and sedatives. RNS may be a treatment option for select patients with SRSE with networks involving eloquent cortex.
- pregabalin / Generic mfg., gabapentin / Generic mfg., carbamazepine / Generic mfg.
A Survey of Anti-Seizure Medication Availability on In-Patient Hospital Formularies in Maryland. Implications for Patients with Intractable Epilepsy and Breakthrough Seizures () - Dec 12, 2021 - Abstract #AES2021AES_1222;
Newer ASMs especially clobazam, brivaracetam, perampanel, and cenobamate which cater to more intractable patients and whose use is in the ascendancy are often not available in emergency rooms when needed most. Some of these ASMs are not easily interchangeable especially in brittle patients.
- Xcopri (cenobamate) / SK Bio, Angelini Group
Medication Resistant Epilepsy in Sturge Weber Syndrome Treated with Brain-Responsive Neurostimulation and Cenobamate () - Dec 12, 2021 - Abstract #AES2021AES_1199;
RNS System allows for tailored therapeutic strategies based on patient response over the course of treatment. Stimulation and electrode polarities may be adjusted to treat a specific region of neocortex.
- lorazepam / Generic mfg.
Epilepsia Partialis Continua Caused by Nonketotic Hyperglycemia and Acute Multifocal Strokes () - Dec 12, 2021 - Abstract #AES2021AES_1176;
Hyperglycemia is thought to lower seizure thresholds by increasing extracellular glutamate supply and gamma-aminobutyric acid usage. This threshold is usually offset by ketones which are thought to counteract the hypoglycemia.
- lorazepam / Generic mfg., midazolam hydrochloride / Generic mfg.
COVID-19 Infection Complicated by Posterior Reversible Encephalopathy Syndrome and De Novo Super Refractory Status Epilepticus () - Dec 12, 2021 - Abstract #AES2021AES_1167;
Seizures may be secondary to direct COVID-19-induced brain damage, endothelial disruption from angiotensin-converting enzyme 2 (ACE-2) receptor dysfunction, and high levels of inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α), interleukin (IL) 1, and IL-8. These changes are also seen in patients with PRES.
- Fycompa (perampanel) / Eisai
Late Perampanel Treatment Reduces the Neuropathological Consequences of Status Epilepticus in a Rat Model () - Dec 12, 2021 - Abstract #AES2021AES_1153;
It also reduced neuronal injury in CA3, thalamus, parietal cortex, piriform and entorhinal cortex, and amygdala. Valproate, levetiracetam and lacosamide (24 mg/kg) failed to reduce neuronal injury.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
Anxiety, Depression and Medication Side Effects as Determinants of Quality of Life in People with Epilepsy () - Dec 12, 2021 - Abstract #AES2021AES_1083;
Female PWE may be more susceptible to anxiety, depression, and medication side effects, with resultant impacts on QOL. Certain ASMs and previous psychiatric diagnoses appear to have differential effects on QOL and ASM side effect profiles which should be taken into account when selecting ASMs.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
Traumatic Brain Injury Associated Intractable Epilepsy and Ketogenic Diet: A Case Report of Successful Treatment of Two Cases () - Dec 12, 2021 - Abstract #AES2021AES_1070;
Later at 23 months of age, he developed asymmetric infantile spasms, which showed greater than 50% seizure reduction with Clobazam treatment... We conclude that there is a need to explore role of KD as an antiepileptic therapy in TBI associated refractory epilepsy.
- gabapentin / Generic mfg., carbamazepine / Generic mfg.
Nonconvulsive Status Epilepticus in the Setting of Cannabidiol Adjunctive Therapy () - Dec 12, 2021 - Abstract #AES2021AES_1048;
CBD may have also triggered NCSE in our patient because of its pharmacokinetic interactions with his other ASMs, specifically by increasing tiagabine levels. There is still a need to better understand CBD’s molecular targets to prevent this rare complication.
- Impact of First Drug Choice on Injuries in Older Adults with New-Onset Epilepsy () - Dec 12, 2021 - Abstract #AES2021AES_1002;
Older adults are still frequently prescribed sub-optimal medications including benzodiazepines. Initial multivariable models suggest that initial prescription of sub-optimal ASMs is associated with an increased risk of 1-year injury.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
Code Seizure: Improving Time to Treatment by Implementation of an Institutional Status Epilepticus Protocol and Treatment Order Set () - Dec 12, 2021 - Abstract #AES2021AES_949;
Median dosing of the most commonly used ASM, levetiracetam, also increased significantly between baseline and post-intervention cohorts. Further study of SE management and the impact on in-hospital and long-term outcomes is warranted.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
Retrospective Study on Safety and Effectiveness of Lacosamide for Neonatal Seizures () - Dec 12, 2021 - Abstract #AES2021AES_921;
The results from this study indicate LCM is being used to treat neonates with seizures, is not associated with safety events attributable to LCM, and may be effective, with half of the patients showing improvement in seizures. Further controlled studies are required to confirm the safety and effectiveness of LCM for neonatal seizures.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
Targeting the Gaps in the Management of Status Epilepticus Through Improved Medication Delivery Algorithms and Education () - Dec 12, 2021 - Abstract #AES2021AES_908;
Implementation of several health care initiatives at our comprehensive epilepsy center has resulted in improved processing of emergent orders for rescue medications and allowed for more efficient delivery of medications to the bedside. Although the differences between current and previously recorded latencies did not reach statistical significance, these results are encouraging and suggest that the education of resident, nurses, and pharmacy staff can improve the care for patients with NCSE.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
A Case of Successful Treatment of Intractable Focal Epilepsy with Transcranial Magnetic Stimulation () - Dec 12, 2021 - Abstract #AES2021AES_889;
TMS influences cortical excitability, is a promising non-invasive means of treating focal epilepsy, and has measurable effects on EEG. Further investigation is needed to determine useful biomarkers for noninvasive brain stimulation.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
Evaluating the Occurrence of Newly Diagnosed Health Conditions Among Neonates Exposed to Intravenous Lacosamide Using Real World Data () - Dec 12, 2021 - Abstract #AES2021AES_867;
Further investigation is needed to determine useful biomarkers for noninvasive brain stimulation. IV LCM in this study appeared to have a favorable safety profile in neonates.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
Efficacy and Safety of Lacosamide in Infants () - Dec 12, 2021 - Abstract #AES2021AES_857;
In addition, lacosamide was well-tolerated with no hepatic, renal, or cardiac side effects seen in any of the patients in this study. Cardiac and hematologic side effects, though reported in the literature, were not seen in our sample.This study is among the first and largest retrospective chart reviews investigating lacosamide in infants less than 2 years old and suggests that lacosamide is both efficacious and well-tolerated in this age group.
- ganaxolone IV / Marinus
IV Ganaxolone in Pediatric Super-Refractory Status Epilepticus: Two Case Presentations () - Dec 12, 2021 - Abstract #AES2021AES_837;
Seizure control was maintained after transitioning to enteric ganaxolone. Further investigation of ganaxolone as a treatment for SRSE is warranted.
- lorazepam / Generic mfg., midazolam hydrochloride / Generic mfg.
Maternal and Fetal Outcomes of Status Epilepticus During Pregnancy in Women with Drug Resistant Epilepsy () - Dec 12, 2021 - Abstract #AES2021AES_685;
Our small cohort showed no maternal mortality and satisfactory fetal outcome in 5 of 6 pregnancies. In contrast to the literature, the SE presentation was not due to noncompliance.
- lorazepam / Generic mfg., levetiracetam / Generic mfg.
Multifocal Myoclonus as a Presentation of Levetiracetam Toxicity () - Dec 12, 2021 - Abstract #AES2021AES_646;
One may hypothesize a dose-dependent effect on myoclonus with more effective binding activation of SV2A receptors at low concentrations and possible quiescence at higher concentrations. Detailed review of additional cases of and risks of potential levetiracetam toxicity would be integral in further understanding its properties and mechanisms of action.References1) Abou-Khalil B. Levetiracetam in the treatment of epilepsy.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
Sphenoidal Encephalocele Causing Nocturnal Frontal Lobe Seizures () - Dec 12, 2021 - Abstract #AES2021AES_616;
The bony defect is probably related to her remote TBI. The formation of this sphenoid encephalocele had been a chronic process, which did not cause neurological symptom until decades later, indicating that frontal lobe encephalocele may be asymptomatic when the size is small.
- ||| Vimpat (lacosamide) / UCB, Daiichi Sankyo, phenytoin / Generic mfg., ketamine / Generic mfg.
Clinical: I agree with your wife. Most often with all those AEDs patients are hypotensive. I prefer prop over midaz but we can’t usually use it. I justify low dose pressors. Up to 10ucg of norepi. I use lacosamide early. Fos v phenytoin is an academic debate. Ketamine is good, not panacea (Twitter) - Dec 6, 2021
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
Time to Administration of Intravenous Piggyback Lacosamide in Hospitalized Patients ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_3844;
- | Vimpat (lacosamide) / UCB, Daiichi Sankyo
Journal: CRMP2 Is Involved in Regulation of Mitochondrial Morphology and Motility in Neurons. (Pubmed Central) - Dec 2, 2021
The CRMP2-binding small molecule (S)-lacosamide ((S)-LCM) prevented an OA-induced increase in CRMP2 phosphorylation at Thr509/514 and Ser522 but not at Thr555, and also failed to alleviate Drp1 phosphorylation...Deletion of CRMP2 with a small interfering RNA (siRNA) resulted in increased mitochondrial fission and diminished mitochondrial traffic. Overall, our data suggest that the CRMP2 expression level and phosphorylation state are involved in regulating mitochondrial morphology and motility in neurons.
- || midazolam hydrochloride / Generic mfg., carbamazepine / Generic mfg., voriconazole / Generic mfg.
Clinical, PK/PD data, Review, Journal: A review of pharmacokinetic drug interactions between antimicrobial and antiseizure medications in children. (Pubmed Central) - Dec 1, 2021
Voriconazole might also be predicted to increase levels of cannabidiol, CBZ, lacosamide, midazolam, and zonisamide. DDIs between ASMs and some antiviral agents are potentially even more frequent and clinically relevant.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Review, Journal: Efficacy of lacosamide and phenytoin in status epilepticus: A systematic review. (Pubmed Central) - Nov 29, 2021
DDIs between ASMs and some antiviral agents are potentially even more frequent and clinically relevant. LCM has comparable efficacy with fewer SAEs as compared to PHT for achieving seizure control in patients with SE.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo, Fycompa (perampanel) / Eisai
Clinical, Journal: Effects of Vagus Nerve Stimulation following Corpus Callosotomy for Patients with Drug-Resistant Epilepsy. (Pubmed Central) - Nov 29, 2021
LCM has comparable efficacy with fewer SAEs as compared to PHT for achieving seizure control in patients with SE. VNS therapy after CC may increase the proportion of responders independent of the addition of novel ASMs.
- methotrexate IV / Generic mfg., gabapentin / Generic mfg., carbamazepine / Generic mfg.
Impact of Anticonvulsant - Methotrexate Interactions on High Dose Methotrexate Clearance and Outcomes in Patients with Primary CNS Lymphoma () - Nov 24, 2021 - Abstract #ASH2021ASH_6249;
Anticonvulsants are an essential component to PCNSL therapy in patients on HD-MTX. They are well tolerated, do not alter HD-MTX clearance in a clinically significant manner and may help improve patient outcomes.
- | carbamazepine / Generic mfg.
Journal: Cardiac Sodium Channel Blockade Due to Antiepileptic Drug Combination. (Pubmed Central) - Nov 21, 2021
We describe the effect of two sodium channel blockers on the heart of a patient with epilepsy. Approximately 30% of patients with epilepsy require combination therapy with antiepileptic drugs for seizure reduction.Lacosamide and carbamazepine are both sodium channel blockers but exert their effects through different mechanisms.Electrocardiogram monitoring is necessary when lacosamide and carbamazepine are used together as this combination may predispose to seizures, conduction abnormalities and dysrhythmia.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal, Video: Efficacy of Lacosamide in a Patient with Refractory Generalized Epilepsy Based on Video Electroencephalography. (Pubmed Central) - Nov 21, 2021
Subsequent LCM titration was successful in achieving a seizure-free status. Our vEEG results suggest that LCM may be a worthwhile AED adjunct in refractory GE patients without a risk of worsening absence seizures.
- | carbamazepine / Generic mfg.
Retrospective data, Journal: Sodium channel blockers are effective for benign infantile epilepsy. (Pubmed Central) - Nov 18, 2021
Our vEEG results suggest that LCM may be a worthwhile AED adjunct in refractory GE patients without a risk of worsening absence seizures. Low-dose LCM was effective and well tolerated in patients with BIE, whereas LEV was insufficiently effective.
- || pregabalin / Generic mfg., gabapentin / Generic mfg., duloxetine / Generic mfg.
Retrospective data, Review: Different Drugs for the Treatment of Painful Diabetic Peripheral Neuropathy: A Meta-Analysis. (Pubmed Central) - Nov 17, 2021
In addition, the efficacy of buprenorphine, tanezumab, fulranumab and others could not be concluded due to insufficient studies...For the results of our meta-analysis, long-term studies are still needed to verify their efficacy and safety in the future. Systematic Review Registration: PROSPERO, identifier: CRD42020197397.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Review, Journal: Pharmacotherapy for Nonconvulsive Seizures and Nonconvulsive Status Epilepticus. (Pubmed Central) - Nov 17, 2021
There are several enteral ASMs that could be used when IV ASM options have been exhausted. Refractory NCSE is not uncommon, and its treatment requires a very judicious selection of ASMs aiming at reducing seizure burden along with management of the underlying condition.
- | Vimpat (lacosamide) / UCB, Daiichi Sankyo
Journal: Therapeutic Drug Monitoring of Lamotrigine, Lacosamide, and Levetiracetam in Dried Capillary Blood - Determination of Conversion Factors for Serum-Based Reference Ranges. (Pubmed Central) - Nov 17, 2021
A simple ratio approach using the mean ratio and Passing-Bablok regression showed the best results for all three AEDs. The VAMS™ technique facilitates the quantitative sample collection of capillary blood and overcomes the drawbacks associated with the classical dried blood spot technique.
- | bumetanide / Generic mfg., carbamazepine / Generic mfg.
Preclinical, Journal: Pathology-selective antiepileptic effects in the focal freeze-lesion rat model of malformation of cortical development. (Pubmed Central) - Nov 11, 2021
Our work adds evidence for the functional relevance of chloride homeostasis in the pathophysiology of microgyrus formation as represented in the focal freeze-lesion model. Further studies in different MCD models and human tissue will be required to validate the effects across different MCD subtypes and species and to assess the translational value of our findings.
- || lamotrigine liquid oral suspension / OWP Pharma
Review, Journal: Feasibility of Using Oral Fluid for Therapeutic Drug Monitoring of Antiepileptic Drugs. (Pubmed Central) - Nov 4, 2021
Using OF may improve the acceptability and accessibility and reduce the cost of AED TDM. Clinical implementation requires standardized collection protocols, more rigorously defined OF reference ranges, and further studies to determine the relevance to clinically important outcomes.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
Cardiac arrest after Sevoflurane-Alfentanil induction in a patient with epileptic encephalopathy treated by Lacosamide ([VIRTUAL]) - Oct 31, 2021 - Abstract #Euroanaesthesia2021Euroanaesthesia_546;
The knowledge of each drug’s mechanisms and interactions should be well-known by the practician and integrated with the patient’s background. Extreme cautious should be taken with recently marketed drugs like lacosamide.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Efficacy and tolerability of Lacosamide for focal epileptic patients: Study from epilepsy clinic in Makkah. (Pubmed Central) - Oct 28, 2021
Extreme cautious should be taken with recently marketed drugs like lacosamide. Lacosamide is an effective well tolerate drug for patients with focal epilepsy.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: The Efficacy and Safety of Lacosamide for Bipolar Depression: A 12-Week Open-Label Pilot Trial. (Pubmed Central) - Oct 28, 2021
Lacosamide is an effective well tolerate drug for patients with focal epilepsy. No abstract available
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Lacosamide-Induced Dyskinesia in Children With Intractable Epilepsy. (Pubmed Central) - Oct 27, 2021
These cases suggest that pediatric patients with dysfunction of the opercular cortex are at increased risk for developing drug-induced dyskinesias on high-dose lacosamide therapy. Practitioners should be aware of this potential side effect and consider weaning lacosamide or video electroencephalography (EEG) for differential diagnosis, particularly in pediatric patients with underlying opercular dysfunction.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Intravenous Lacosamide in Seizure Clusters: Dose and Efficacy. (Pubmed Central) - Oct 27, 2021
In adults with SC, a loading dose of IV LCM of 200 mg or more achieved 89% response rate in this cohort. Loading doses of less than 300 mg caused mild side effects only.
- | Vimpat (lacosamide) / UCB, Daiichi Sankyo
Journal: Lacosamide serum concentrations during pregnancy. (Pubmed Central) - Oct 27, 2021
There were no significant changes in seizure frequency and none of the neonates had teratogenic findings at time of birth. We are the first to report a case series on the changes in LCM levels during pregnancy with significant decreased LCM DNC levels during the second and third trimesters in comparison to pre-pregnancy values.
- | Vimpat (lacosamide) / UCB, Daiichi Sankyo
Preclinical, Journal: Effect of lacosamide on neuroinflammation-mediated seizures comorbid with depression in C57BL/6 mice- Role of kynurenine pathway. (Pubmed Central) - Oct 27, 2021
Lacosamide has shown positive effects against neuroinflammation-mediated model of seizures comorbid with depression by reducing hippocampal kynurenine levels. No reduction in the PILO group is suggestive of the principal contribution of its anti-inflammatory and antioxidant activity in its anti-seizure potential in this model via KP.
- | Vimpat (lacosamide) / UCB, Daiichi Sankyo
Vimpat is almost as bad TBH. Since it’s scheduled as a narcotic. So great!! (Twitter) - Oct 26, 2021
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Thymoma Associated with Autoimmune Multifocal Cortical Encephalitis and Subsequent Myasthenia Gravis () - Oct 21, 2021 - Abstract #ANA2021ANA_408;
Our case report is only the third reported case of thymoma-associated multifocal cortical encephalitis, which shows that autoimmune encephalitis can extend to cortical regions outside the limbic system. We should consider autoimmune encephalitis in the differential diagno sis of patients with myasthenia gravis or thymoma who develop new cognitive symptoms.
- carbamazepine / Generic mfg.
[VIRTUAL] Total Daily Dosage of Anti-Epileptic Drugs in Women with Epilepsy with Subsequent Pregnancies () - Oct 21, 2021 - Abstract #ANA2021ANA_222;
This variation may reflect differences in the timing of level testing, variability in practitioner dosage change during different pregnancies amongst other factors. The doses used during an initial pregnancy may be useful in guiding dose management in successive pregnancies, but frequent testing of levels may still be needed.